ClinicalTrials.gg
RecruitingNCT07850310Updated Oct 27, 2026

A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)

A Phase 1 interventional study of MK-8644 and Placebo for MK-8644 in Psoriasis and Healthy, sponsored by Merck Sharp & Dohme LLC. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Updated Oct 27, 2026Now RecruitingFirst site in Australia+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Psoriasis by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Merck & Co., Inc.

Planned enrollment
6th of 14
132 · median 45
Started
2026
the only one that year
Phase 1
4 of 18
1 open now
Registered
18th of 18
by date

Among the 18 studies in Psoriasis by Merck & Co., Inc, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 1, and was the 18th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 18 studies in Psoriasis by Merck & Co., Inc is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Psoriasis by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.

This trial will help researchers learn about the safety of MK-8644 and if participants tolerate it. Tolerate means participants will receive MK-8644 in the trial unless they need to stop it due to health problems.

03

Conditions studied

  • Psoriasis
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is in good health
  • Has a between 18 and 36 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Has a history of cancer.
  • Has a history of significant multiple and/or severe allergies.
  • Has positive test(s) for surface antigen (HBsAg), antibodies, tuberculosis, or .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    MK-8644

    Participants receive MK-8644 orally under fasted or fed conditions depending on randomization.

    Drug: MK-8644

  • Placebo comparator
    Placebo

    Participants receive matching placebo for MK-8644 orally under fasted or fed conditions depending on randomization.

    Drug: Placebo for MK-8644

Interventions

  • DrugMK-8644

    Oral administration

  • DrugPlacebo for MK-8644

    Oral administration

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

    Time frame: Up to approximately 43 days

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

    Time frame: Up to approximately 28 days

Secondary outcomes

  1. Plasma Concentration at 24 Hours (C24) of MK-8644

    Blood samples will be collected at designated timepoints to determine the C24 of MK-8644

    Time frame: At designated timepoints up to 24 hours post-dose

  2. Maximum Plasma Concentration (Cmax) of MK-8644

    Blood samples will be collected at designated timepoints to determine the Cmax of MK-8644

    Time frame: Predose and at designated timepoints up to 4 days post-dose

  3. Time to Maximum Plasma Concentration (Tmax) of MK-8644

    Blood samples will be collected at designated timepoints to determine the Tmax of MK-8644

    Time frame: Predose and at designated timepoints up to 4 days post-dose

  4. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-8644

    Blood samples will be collected at designated timepoints to determine the AUC0-Last of MK-8644

    Time frame: Predose and at designated timepoints up to 4 days post-dose

  5. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-8644

    Blood samples will be collected at designated timepoints to determine the AUC0-Inf of MK-8644

    Time frame: Predose and at designated timepoints up to 4 days post-dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 13 months after the start.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 13 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartActual
Oct 20, 2026
Primary completionEst.
Dec 13, 2027
CompletionEst.
Dec 13, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
1 site added — first site in Australia
Show site
  • Nucleus Network ( Site 0001) · Melbourne, Australia
Oct 27, 2026
Start date
Oct 6, 2026→Oct 20, 2026 (actual)
Oct 27, 2026
Contact
Study contact now listed: added T•••@merck.com · •••8839. See the current contact
Oct 27, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Australia
    Show site
    • Nucleus Network ( Site 0001) · Melbourne, Australia
    Start date Oct 6, 2026→Oct 20, 2026 (now actual)
    Contact Study contact now listed: added T•••@merck.com · •••8839. See the current contact
    + 2 other changes: verification date and references
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850310
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 20, 2026
Primary completion
Dec 13, 2027 (estimated)
Completion
Dec 13, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Toll Free Number
Contact
Trialsites@merck.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion